American Society of Hematology

Fig. 2.

$Fig. 2. AP20187 increases the fraction of GFP-positive cells in the bone marrow. / Sequential flow cytometric analysis of GFP-expressing total nucleated cells (A), CD34-expressing cells (B), and GFP-expressing CD34+ cells (C) shows a reversible, CID-dependent increase in the fraction of transduced cells. The effect is most pronounced in the CD34+ cell compartment. (D) Scatter plots of bone marrow cells obtained before and after AP20187 administration. GFP expression is shown on the x-axis, CD34-expression on the y-axis. These plots demonstrate the substantial expansion of CD34/GFP double-positive cells in response to CID. (E) Selection was confirmed on the DNA level by quantitative real-time PCR. Each data point in panel E represents the mean of 2 independent measurements, each carried out in duplicate. Error bars depict the range between the 2 experiments. The black rectangles in panels A-C and E indicate the periods of AP20187 treatment.$

AP20187 increases the fraction of GFP-positive cells in the bone marrow.

Sequential flow cytometric analysis of GFP-expressing total nucleated cells (A), CD34-expressing cells (B), and GFP-expressing CD34⁺ cells (C) shows a reversible, CID-dependent increase in the fraction of transduced cells. The effect is most pronounced in the CD34⁺ cell compartment. (D) Scatter plots of bone marrow cells obtained before and after AP20187 administration. GFP expression is shown on the x-axis, CD34-expression on the y-axis. These plots demonstrate the substantial expansion of CD34/GFP double-positive cells in response to CID. (E) Selection was confirmed on the DNA level by quantitative real-time PCR. Each data point in panel E represents the mean of 2 independent measurements, each carried out in duplicate. Error bars depict the range between the 2 experiments. The black rectangles in panels A-C and E indicate the periods of AP20187 treatment.

This Feature Is Available To Subscribers Only